Teva Pharmaceuticals (NYSE: TEVA) released its full-year 2013 forecast, which missed top-line estimates by 4% and bottom-line estimates by 11%. The markets haven't taken the news too badly, opening down 3% but rallying back during the day to a slight gain. In this video, Motley Fool health care analyst David Williamson tells us where these low figures may have come from and what Teva may have in store for 2013.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Teva Guides for Disappointment
NYSE: TEVA
Teva Pharmaceutical Industries

Teva's new CEO sets expectations low for this year.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Amarin plc (ADR). Follow him on Twitter @MotleyDavid.
The Motley Fool owns shares of Momenta Pharmaceuticals. Motley Fool newsletter services recommend Biogen Idec and Momenta Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned





*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.